Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review

Blessie Elizabeth Nelson1*, Angelina Hong2 and Bagi Jana3

1 Department of Hematology and Oncology, University of Texas Medical Branch, Galveston, TX, United States, 2 School of Medicine, University of Texas Medical Branch, Galveston, TX, United States, 3 Department of Hematology and Oncology, MD Anderson Cancer Center, Houston, TX, United States

Urothelial carcinoma therapy is a rapidly evolving and expanding field. Traditional cytotoxic chemotherapy regimens have not produced optimal long-term outcomes, and many urothelial cancer patients have comorbidities that disqualify them as chemotherapy candidates. In recent years, a plethora of novel therapeutic agents that target diverse molecular pathways has emerged as alternative treatment modalities for not only metastatic urothelial carcinoma, but also for muscle-invasive bladder cancer and non-muscle invasive bladder cancer in adjuvant and definitive settings. This review paper aims to discuss the various categories of therapeutic agents for these different types of urothelial cancer, discussing immunotherapy, antibody-drug conjugates, kinase inhibitors, CAR-T cell therapy, peptide vaccination, and other drugs targeting pathways such as angiogenesis, DNA synthesis, mTOR/PI3K/AKT, and EGFR/HER-2.

Keywords: urothelial carcinoma, molecular targets, FDA approvals, bladder cancer, clinical trials, targeted therapy

INTRODUCTION

Bladder cancer or urothelial carcinoma (UC) of the bladder is a common and deadly malignancy worldwide, and chemotherapy has produced limited improvement in outcomes. There are 550,000 new cases of UC globally each year, and UC accounts for about 2.1% of all deaths due to cancer. Women have a 0.27% lifetime risk of acquiring UC, whereas this risk is 1.1% in men (1). Management of UC depends on whether the malignancy is invasive or non-invasive. Low to intermediate risk non-muscle invasive bladder cancer (NMIBC) is treated with transurethral resection of bladder tumor (TURBT) followed by surveillance. For high risk NMIBC, cystectomy or intravesical induction therapy with chemotherapy followed by Bacille Calmette-Guerin (BCG) maintenance therapy or BCG therapy with maintenance therapy may also be considered. For NMIBC patients refractory to BCG therapy, cystectomy is first-line management. Localized muscle-invasive bladder cancer (MIBC) is treated with radical cystectomy and neoadjuvant chemotherapy or radical cystectomy in chemotherapy ineligible candidates or bladder preservation strategies with concurrent chemoradiation. Upfront therapy for muscle-invasive UC is neoadjuvant chemotherapy in patients who are eligible to receive platinum-based therapy. Standard chemotherapy for metastatic UC is platinum-based, and includes three different drug regimens:
methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC),
dose dense MVAC, and lastly gemcitabine with cisplatin (GC)
(2). There has been extensive research on chemotherapy for UC;
platinum-based therapy was discovered to improve outcomes in
locally advanced UC patients in the 1980s, with MVAC being the
first regimen studied (3). In 2000, a phase III trial comparing the
outcomes in advanced/metastatic UC patients treated with
MVAC versus GC found that the survival rates are similar in
both arms, but GC therapy had fewer toxic effects than MVAC.
Although the GC arm experienced more grade 3 anemia and
thrombocytopenia events, but the MVAC arm had a greater
occurrence of grade 4 neutropenia, neutropenic fever,
neutropenic sepsis, mucositis, and alopecia (4). There are also
alternative chemotherapy regimens for patients who are
ineligible for cisplatin therapy. De Santis et al.’s 2012 phase II/
III trial compared the outcomes of gemcitabine with carboplatin
versus methotrexate with carboplatin and vinblastine (MCAVI)
in patients unfit for cisplatin-based chemotherapy. They found
that there were no significant differences in efficacy between the
two arms, although the incidence of severe acute toxicities (e.g.,
death, grade 3 or 4 renal toxicity, neutropenic fever) occurred
more frequently in the MCAVI group (5).

However, metastatic UC still carries a particularly poor
prognosis. After treatment with these chemotherapy regimens,
the approximate median survival is only thirteen to fifteen
months (4, 6). There are a handful of possible molecular
mechanisms that may explain this suboptimal response to
cytotoxic chemotherapy. Recent studies have revealed that UC
patient differences in the expression of various proteins, such as
matrix metalloproteinase-7 and syndecan-1, affect the prognosis
following chemotherapy (7, 8). Additionally, individual variations
in tumor-infiltrating B-cell activity have significant prognostic
value for MIBC patients (9), and long noncoding miRNAs have
also been found to regulate muscle-invasive UC proliferation and
resistance to chemotherapy (10). Considering this suboptimal
response to chemotherapy, a growing body of research is
exploring targeted molecular therapy as an alternative to
traditional chemotherapy. Additionally, promising biomarkers
such as tumor mutational burden continue to be investigated and
can provide prognostic information to guide developing
bladder cancer treatments such as immunotherapy (11).

The Cancer Genome Atlas (TCGA) is a practice changing
cancer genomics program which molecularly characterized over
20,000 primary cancers and matched normal samples spanning
33 cancer types (12). In 2020, a molecular classification of MIBC
on basis of 1750 MIBC transcriptomic profiles from 18 datasets
comparing six molecular classification schemes was reported. Six
molecular classes were identified namely luminal papillary,
luminal non-specified, luminal unstable, stroma-rich, basal/
squamous, and neuroendocrine-like (13). Each consensus class
is associated with differing stromal and genetic alteration that
could identify who would more likely respond to immunotherapy
or targeted therapy (14).

This paper discusses these categories of novel therapy that each
have diverse molecular targets, which can affect host immune
response as well as tumor activity. There is a real unmet need for
development of therapeutic strategies for BCG refractory NMIBC
setting, perioperative setting in MIBC, and platinum unfit
population. Literature for these various UC therapies will be
reviewed in the context of localized and metastatic MIBC and
NMIBC management. Firstly, the agents for UC management that
are currently or formerly FDA-approved or have promising phase
III trial results will be discussed. The UC therapies with only phase
I or II trials or ongoing phase III trials will then be outlined.
Although more research is still needed, the rapidly developing field
of genomic sequencing and biomarker stratification holds promise
for targeted molecular therapy in UC realm (15).

THERAPEUTIC AGENTS FOR ADVANCED
OR METASTATIC UROTHELIAL
CARCINOMA

Immunotherapy

Checkpoint inhibitors comprise one of the most promising fields
for metastatic or advanced UC therapy. There are two main
categories of checkpoint inhibitor therapy: agents targeting
programmed cell death protein 1 (PD-1) or programmed cell
dehigand 1 (PD-L1) and agents targeting cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) in Figure 1.
Although these agents are not first-line therapy for UC,
multiple phase II and III trials have demonstrated checkpoint
inhibitors’ significant roles in advanced/metastatic UC refractory
to standard platinum-containing chemotherapy. Since 2016, the
checkpoint inhibitors avelumab, atezolizumab, durvalumab,
nivolumab, and pembrolizumab have received FDA (Food and
Drug Administration) approval as treatment agents for bladder
cancer (17). However, as of 2021, two of these agents,
atezolizumab and durvalumab, have since been withdrawn (18,
19). PD-L1 expression is a potential predictive biomarker for
PD-1/PD-L1 immunotherapy efficacy, but this connection is not
yet clearly established. For example, some malignancies
demonstrate higher responses to immunotherapy with greater
PD-L1 expression, whereas other tumors’ responses to treatment
have an inverse relationship with their PD-L1 expression.
Additionally, the use of immunohistochemistry to quantify
PD-L1 expression is limited by variation in tissue preparation
and processing steps. There are also challenges in differentiating
stained tumor cells from immune cells, primary tumor biopsies
versus metastatic ones, and oncogenic PD-L1 expression versus
induced expression (20). The timeline of FDA approvals for
novel UC therapies from 2015 to 2021 is presented in Table 1.

Nivolumab targets the PD-1 receptor and was approved by
the FDA in February 2017 (41). In the CheckMate 032 trial, a
2016 phase I/II study, nivolumab monotherapy in recurrent,
metastatic UC produced an ORR of 24.4% (26). The next year,
Sharma et al. published the CheckMate 275 trial, a phase II study
involving nivolumab monotherapy in patients with metastatic or
surgically unresectable UC that was refractory to platinum-based
therapy. 265 patients were treated with nivolumab, and 52
patients (19.6%) achieved objective response. Although there
was a higher ORR in the patient groups with a higher percentage of PD-L1 expression, significant clinical improvement was observed in all groups regardless of PD-L1 expression. 48 (18%) experienced grade 3-4 adverse events (AE), the most common being grade 3 fatigue and diarrhea (27). A 2019 global analysis of the CheckMate 275 trial reached the same conclusions as those found in the original trial publication (42). In the adjuvant setting, the CheckMate274 phase 3, randomized, double-blind, multicenter trial compared 353 patients in nivolumab arm and 356 patients in the placebo arm among patients with high-risk muscle-invasive urothelial carcinoma (with primary tumor sites including bladder, ureter, or renal pelvis) after radical surgery.
Patients were allowed but not required to have received neoadjuvant cisplatin. At 20 months median follow up, median disease-free survival was significantly longer for patients receiving nivolumab at 21 months compared to placebo at 11 months (HR: 0.70, 95% C.I. 0.54-0.89). A similar effect was observed in the PD-L1 ≥ 1% population where percentage of patients was 74.5% and 55.7%, respectively (HR 0.53, 95% C.I. 0.34-0.84). Grade 3 or 4 treatment-related adverse events occurred in 17.9% and 7.2% of patients in the nivolumab and placebo arms, respectively (43).

Avelumab is a monoclonal IgG antibody that targets PD-L1. It received accelerated approval by the FDA in May 2017 for treatment of locally advanced/metastatic UC that progressed during or after platinum-containing chemotherapy or within 1 year of receiving neoadjuvant or adjuvant platinum-containing chemotherapy (44). Avelumab then received approval in June 2020 for maintenance therapy in patients with locally advanced or metastatic UC that did not progress after first line platinum-containing chemotherapy (45). Phase I studies have demonstrated that avelumab is well-tolerated in patients with refractory, metastatic UC (29, 30). There is a randomized multicenter phase II study in the recruitment stage that compares the treatment outcomes of gemcitabine and cisplatin (GC) versus GC plus avelumab in patients with advanced UC. 90 patients are stratified by Karnofsky performance status and metastasis (visceral or non-visceral) (46). The recent JAVELIN Bladder 100 phase III trial compared the outcomes of avelumab with best supportive care (BSC) versus BSC alone for maintenance treatment of advanced/metastatic UC that did not worsen from first-line chemotherapy. The median OS in all patients, regardless of PD-L1 status in the tumors, was 21.4 months in the arm receiving avelumab, compared to an OS of only 14.3 months in the BSC arm (HR 0.69, CI 0.40 to 0.79, P < 0.001). In the overall population, the median PFS in the avelumab group was 3.7 months, compared to only 2.0 months in the control (HR 0.62, CI 0.52 to 0.75). In the PD-1 positive population, the median PFS was 5.7 months in the avelumab group and 2.1 months in the control (HR 0.56, CI 0.43 to 0.73). 11.9% of patients in the avelumab arm had treatment discontinued due to AEs, and the most common AEs grade 3 or greater in the avelumab group were UTI and anemia. These results demonstrated avelumab’s powerful role as first-line maintenance therapy for advanced UC, thus establishing a new standard of care for this type of UC (47). The stratified analysis found that there was a survival benefit with avelumab over the control group in all of the subgroups, regardless of whether the patients had first received cisplatin with gemcitabine or carboplatin with gemcitabine (48).

Pembrolizumab blocks PD-1, and in 2017 received accelerated FDA approval for patients with advanced/metastatic UC who are ineligible for cisplatin-containing chemotherapy. In 2018, the FDA modified this indication so that pembrolizumab could be used only in cisplatin-ineligible patients and high PD-L1 expression with CPS (Combined Positive Score) >10, or in patients who are unfit for any platinum therapy, regardless of their PD-L1 expression as the KEYNOTE-361 trial showed decreased survival in patients with PD-L1-low status in the pembrolizumab monotherapy arm (49, 50). It also received regular FDA approval for advanced/metastatic UC progression during/after first-line platinum chemotherapy or within 12 months of receiving adjuvant/neoadjuvant platinum chemotherapy (51). Pembrolizumab’s accelerated approval was based upon the phase II KEYNOTE-052 trial’s data, which treated 370 advanced/metastatic UC patients who were not eligible for cisplatin-based chemotherapy; median follow-up was 5 months, and the ORR was 28.6% (31, 51). Vuky et al.’s 2020 paper examined the long-term outcomes of the KEYNOTE-052 patients, with a minimum follow-up time of 2 years since the last patient was enrolled. The ORR was 28.6%, and the median response duration was 30.1 months. 33 (8.9%) of patients had complete response, and 73 (19.7%) achieved partial response (52). Regular approval was given based upon the results of the phase III KEYNOTE-045 trial, where 542 patients with advanced UC that progressed or recurred following platinum-based chemotherapy were assigned to receive either pembrolizumab or the investigator’s choice of paclitaxel, docetaxel, or vinflunine. The median OS was 10.3 months in the group receiving pembrolizumab, compared to 7.4 months in the chemotherapy group (HR 0.73, CI 0.59 to 0.91, P = 0.002). There were no significant differences in the duration of PFS between the two treatment arms (HR 0.98, CI 0.81 to 1.19, P = 0.42) (51, 53). However, the phase III KEYNOTE-361 trial involved 1010 patients with untreated advanced/metastatic or unresectable UC, with an Eastern Cooperative Oncology Group (ECOG) group score of 2 or lower and did not find a significant survival benefit with pembrolizumab regimens. Patients were randomly assigned to receive either pembrolizumab with gemcitabine, pembrolizumab alone, or chemotherapy alone. The median PFS in the pembrolizumab with chemotherapy group was 8.3 months versus 7.1 months in the chemotherapy only group (HR 0.78, CI 0.65 to 0.93, P = 0.0033). The median OS was 17.0 months in the pembrolizumab with chemotherapy arm, versus 14.3 months in the chemotherapy arm (HR 0.86, CI 0.72 to 1.02, P = 0.0407). The most common grade 3-4 AE was anemia (104 [30%] of 349) in the pembrolizumab and chemotherapy group. In the pembrolizumab only arm, diarrhea, fatigue and hyponatremia were the most frequent grade 3-4 AEs, each occurring in 4 (1%) of the 302 patients (50).

Atezolizumab targets PD-L1 and was initially FDA-approved in May 2016 for locally advanced/metastatic UC that worsened during or after platinum-based chemotherapy, or within 1 year of platinum-based chemotherapy, before or after surgical intervention (54). In 2018, the FDA modified this indication to be used either for patients ineligible for cisplatin with PDL-1 stained tumor infiltrating cells >5%, or for patients ineligible for any platinum-based therapy, regardless of PD-L1 expression (49). However, in March 2021, Roche voluntarily withdrew the FDA indication for atezolizumab for advanced/metastatic UC previously treated with platinum-based therapy (18). Rosenberg et al.’s 2016 phase II trial administered atezolizumab to 310 patients who had locally advanced or metastatic UC refractory to platinum-based chemotherapy. The treatment was appropriately tolerated, with an overall response rate of 15%, regardless of PD-
L1 expression status of the infiltrating immune cells (21). Additionally, the IMvigor 210 study published in 2017 found that UC patients who continued atezolizumab therapy after RECIST v.1.1 progression occurred had a median overall survival (OS) of 8.6 months, compared to a median post-progression OS of 6.8 months in those receiving an alternative treatment (22). The phase III IMvigor 211 trial involved patients with metastatic UC that progressed after platinum-based therapy, who were randomly assigned to receive either atezolizumab or the investigator’s choice of chemotherapy (vinflunine, paclitaxel, or docetaxel). The study’s primary endpoint of improved OS in patients with PD-L1 positive tumors was not achieved (55). The IMvigor130 trial, a multicenter phase III study published in 2020, involved 1213 patients with advanced/metastatic UC. Patients were randomly placed into one of three treatment groups: atezolizumab with platinum-based chemotherapy, atezolizumab alone, or platinum-based chemotherapy with a placebo. In the combination therapy group, median PFS was 8.2 months (CI 6.5 to 8.3), compared to 6.3 months (CI 6.2 to 7.0) in the chemotherapy only group (HR 0.82, CI 0.70 to 0.96, P = 0.007). The median OS in the combination therapy arm was 16 months (CI 13.9 to 18.9), versus 13.4 months (CI 12.0 to 15.2) in the chemotherapy only arm (HR 0.83, CI 0.69 to 1.00, P = 0.027). The combination therapy arm had a safety profile similar to atezolizumab or platinum-based chemotherapy used alone (23). Additionally, in the spring of 2021 the FDA panel has voted for continued support of the accelerated approval of atezolizumab as frontline treatment in cisplatin-ineligible advanced/metastatic UC until the final analysis of the IMvigor 130 trial is released in late 2022 (56). Additionally, the phase III IMvigor 010 trial studied adjuvant atezolizumab therapy in MIBC patients with ECOG score 0-2 and high-risk of recurrence after primary resection. However, the endpoint of disease-free survival was not met. Of the 390 patients in the atezolizumab arm, the most common grade 3-4 AEs were urinary tract infection [31(8%)], pyelonephritis [12(3%)], and anemia [8(2%)].

Durvalumab is another human monoclonal antibody that binds to PD-L1, initially approved by the FDA for advanced UC in February 2017 (58). In a 2017 phase I/II open-label study, Powles et al. assessed the safety profile and efficacy of durvalumab in patients with either locally advanced or metastatic UC. Among 191 patients, the ORR was 17.8%, 3.7% of patients achieved CR, overall survival was 18.2 months, and the median PFS was 1.5 months. 6.8% of patients experienced grade 3-4 treatment-related adverse effects (25). The most common grade 3-4 AEs in the overall population receiving durvalumab were fatigue [16(1.6%) out of 970 patients], elevated AST [11(1.1%)], and elevated GGT [8(0.08%)]. There is also a phase II trial in the recruitment phase that will examine safety and efficacy of dose dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in combination with the checkpoint inhibitors durvalumab and tremelimumab, which targets CTLA-4 rather than PD-L1, for patients with muscle-invasive UC (59). However, like atezolizumab, durvalumab was withdrawn by its developer AstraZeneca as therapy for locally advanced or metastatic UC refractory to chemotherapy in February 2021 (60). The phase III trial DANUBE compared durvalumab with or without tremelimumab versus first-line chemotherapy for stage IV UC but failed to reach its primary end point of OS. The most common grade 3-4 AE was elevated lipase in the durvalumab-only group [7(2%) out of 345 patients] and in the durvalumab with tremelimumab group [16(5%) of 313] (61).

Ipilimumab is a CTLA-4 inhibitor that has not yet been FDA-approved for UC therapy, however, it is a promising therapy when combined with another checkpoint inhibitor such as nivolumab. Sharma et al.’s 2019 multicohort study CheckMate 032 suggested that combination treatment with ipilimumab and nivolumab is a safe regimen that produces greater antitumor outcomes than if either of these therapies were given alone. Patients with metastatic or locally advanced UC were randomized to either a nivolumab 3 mg/kg per 2 weeks monotherapy group (N3), nivolumab 3 mg/kg with ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks (N3I1), or nivolumab 1 mg/kg with ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks (N1I3). The ORRs in the N3, N3I1, and N1I3 arms were 25.6%, 26.9%, and 38.0% respectively. The median response duration was greater than 22 months in all arms. Across all of the treatment arms, the most common therapy-related AEs were fatigue, elevated AST and ALT, pruritis, rash, diarrhea, and reduced appetite. Grade 5 immune-related AE occurred only in the N3 and N3I1 arms (28). In the neo-adjuvant setting, the NABUCCO trial published in 2020 treated 24 stage III UC patients with two doses of ipilimumab then two doses of nivolumab before resection of the malignancy. 23 of the 24 patients achieved the primary endpoint of feasibility to resect within 12 weeks of initiating treatment, and 11 (46%) patients showed a complete pathological response, the secondary endpoint (62). The long-term follow-up data also demonstrate the N1I3 arm’s therapeutic promise. The median OS in the N1I3 group was the longest at 15.3 months, compared to 9.9 months in the N3 group and 7.4 months in the N3I1 group. The N3I1 also produced the greatest ORRs per both investigator review and blinded independent review (42% and 38%, respectively) (63). The ongoing phase III CheckMate 901 trial is studying the outcomes in previously untreated UC patients who are given the N1I3 regimen or standard of care chemotherapy (NCT03036098) (64).

**Targeting FGFR**

The FGFR/FGF pathway is involved in the development of various malignancies, affecting the major signaling pathways for tumor proliferation (Figure 1). Some therapeutic agents are nonselective, targeting all FGFR receptors, whereas others are more selective. Erdafitinib gained FDA approval as therapy for locally advanced or metastatic UC with an FGFR2 or FGFR3 mutation in April 2019 (65). Erdafitinib is a FGFR1-4 inhibitor that has a manageable safety profile in patients with advanced tumors such as UC (36). A phase II trial published in 2019 found that erdafitinib produced a 40% ORR in patients with metastatic...
UC who progressed after least one course of chemotherapy or 12 months of adjuvant or neoadjuvant chemotherapy and possibly immunotherapy, with a median PFS of 5.5 months and median OS of 13.8 months. Out of the 99 patients, the most common grade ≥3 AEs included hyponatremia (11%), stomatitis (10%), asthenia (7%), nail dystrophy (6%), and urinary tract infection (5%) (37).

Enfortumab Vedotin
Enfortumab vedotin (EV) gained FDA approval in December 2019 for the treatment of locally advanced or metastatic UC in patients who had already received a PD-1 or PD-L1 inhibitor and adjuvant or neoadjuvant platinum-containing chemotherapy (66). It is an antibody drug conjugate (ADC) that targets the adhesion molecule Nectin-4, which is expressed on many UC cells (Figure 1). After binding to Nectin-4, the ADC is internalized by the tumor cell and induces cytotoxic effects via disruption of microtubule function, which is accomplished by monomethyl auristatin E, the drug that is conjugated to the antibody (67). The phase I trial EV-101 administered single-agent EV to patients with solid malignancies expressing Nectin-4, including metastatic UC. The therapy was well tolerated, the ORR was 43% with a median OS of 12.3 months, and OS was 51.8% at 1 year (38). In a phase II single-arm EV-201 trial involving patients with advanced/metastatic UC previously treated with platinum chemotherapy and PD-1 or PD-L1 inhibitors, EV therapy produced an ORR of 44% with 12% having CR, median response duration of 7.6 months, and minimal adverse treatment related events (39). The phase III EV-301 trial compared the outcomes of patients treated with EV versus chemotherapy (investigator’s choice of docetaxel, paclitaxel, or vinflunine) following platinum and checkpoint inhibitor therapy. The OS in the EV group was 12.88 months, compared to only 8.97 months in the chemotherapy group (HR 0.7, CI 0.56 to 0.89, P = 0.001). The EV group also had a greater PFS than the chemotherapy group (5.55 months versus 3.71 months, HR 0.62, CI 0.51 to 0.75, P < 0.001). Among 296 patients in the EV arm, the most common grade ≥3 AEs were maculopapular rash [22(7.4%)], fatigue [19(6.4%)], and reduced neutrophil count [18(6.1%)] (68). The ongoing phase III EV-302 trial will compare the outcomes of previously untreated UC patients who are given either EV with pembrolizumab or gemcitabine with platinum-based chemotherapy (NCT04223856).

Antibody-Drug Conjugates
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate containing SN-38, a metabolite in irinotecan which inhibits the activity of topoisomerase (Figure 1). In a phase I trial, 6 patients with metastatic UC refractory to platinum therapy were treated with IMMU-132. This agent was well tolerated overall, and three patients had significant response, with a PFS 6.7-8.2 months, and OS 7.5-11.4 months (40). Phase II of this trial was completed in April 2021 (NCT01631552). Additionally, the phase II ‘TROPHY’ trial administered IMMU-132 to locally advanced or metastatic UC who previously received platinum-based chemotherapy and either a PD-1 or PD-L1 inhibitor. The ORR was 27.7%, and median duration of response of 7.2 months (NCT03547973). In April 2021, sacituzumab govitecan received accelerated FDA approval for treatment of advanced UC (69).

Targeting Angiogenesis
VEGF receptors play a prominent role in tumor growth and have been studied as combination therapy with platinum-based chemotherapy for advanced UC. Although ramucirumab is not FDA-approved for the management of UC, it may provide a promising alternative to standard chemotherapy regimens in the future. A phase III randomized, double-blind trial administered ramucirumab in combination with placebo or IV docetaxel therapy for patients with advanced/metastatic UC who progressed during or after platinum-based therapy. The PFS in the ramucirumab plus docetaxel group was 4.07 months (HR 0.696, CI 0.573 to 0.845, P = 0.0002), which was significantly longer than the PFS of 2.76 months in the docetaxel only group. Median OS was 9.4 months in the combination therapy group compared to only 7.9 months in the docetaxel only group (HR 0.887, CI 0.724 to 1.086, P = 0.25). The most common grade 3 or greater AEs in the ramucirumab with docetaxel group were febrile neutropenia [24(9%) out of 258 patients], reduced neutrophil count [23(9%)], fatigue [17(7%)], hypertension [11(4%)], and diarrhea [8(3%)]. Although these results show promise for ramucirumab in the future for advanced UC management, the generalizability of this study is limited by its particular inclusion and exclusion criteria. For example, eligible patients must have had disease progression according to the Response Evaluation Criteria in Solid Tumors (RESIST) within 14 months or less after receiving platinum-based chemotherapy. The investigators allowed patients who had previously been treated with one checkpoint inhibitor to be included in the study, so long as they had relapsed within 24 months or receiving a platinum-containing treatment plan. Patients who had received more than one treatment of systemic chemotherapy for relapsed or metastatic UC were not eligible (70).

NOVEL MOLECULAR TARGETS FOR MANAGEMENT FOR NON-MUSCLE INVASIVE BLADDER CANCER

Immunotherapy
In January 2020, pembrolizumab also gained FDA approval as treatment for NMIBC with carcinoma in situ that is unresponsive to Bacillus Calmette-Guerin (BCG) (71). The phase II KEYNOTE-057 trial (NCT02625961) administered pembrolizumab monotherapy in high-risk NMIBC (T1, high grade Ta and/or carcinoma in situ [CIS] only) patients, involving one cohort of CIS patients with or without papillary tumors that failed BCG therapy. The published results of the cohort indicate that pembrolizumab has significant activity, with an appropriate safety profile. The CRR at 3 months was 38.8%. In 80.2% of the patients, CR was durable at 6 months, and grade 3 or 4 treatment related AEs only occurred in 12.6% of the cohort. The CRRs were
44.6%, 41.7%, and 28.0% for patients with CIS alone, CIS with T1 tumors, and CIS with high-grade Ta tumors, respectively. 75% of patients demonstrated complete response for ≥ 6 months, and 53% for ≥ 9 months. Out of 101 patients, the most common grade 3-4 treatment related AEs were arthralgia (2%) and hyponatremia (3%) (32). The KEYNOTE-676 trial, which will study the efficacy of pembrolizumab with BCG treatment in high-risk NMIBC patients, is currently in the enrollment phase (NCT03711032).

**Immunomodulators**

Keyhole limpet hemocyanin (KLH) is a large carrier protein that can carry multiple tumor antigens to stimulate significant antibody production. Lammers et al. conducted a phase III trial comparing the outcomes of immunotherapy with adjuvant KLH versus immunotherapy with mitomycin C. Among the NMIBC patients who received KLH, 61% developed recurrence, whereas only 34% of those who received MM had recurrence. Median RFS in the KLH group compared to the MM group was 106 weeks versus 297 weeks (approaching significance P = 0.05, log-rank test). The majority of the AEs in both arms were mild, with fever, fatigue, and flu-like symptoms occurring more frequently in the KLH group (72). However, a 2017 retrospective analysis of this trial argues that outcomes from each drug regimen may have been skewed by operator dependence of the surgeons performing the trial (73).

**Gene Therapy**

Nadofaragene firadenovec is an intravesical therapy comprised of a recombinant adenovirus that delivers the human interferon α–2b gene to the bladder epithelial cells. A phase III involved 151 BCG-nonresponsive NMIBC patients, who each received at least one dose of intravesical nadofaragene firadenovec. Additional doses were given at month 3, 6 and 9 if there was no high-grade recurrence. Out of 103 patients with carcinoma in situ, 55 (53.4%) had complete response within 3 months of receiving the first dose, and 25 out of the 55 patients (45.5%) showed maintained response at 12 months. Only 6 (4%) patients experienced grade 3 adverse events, the most common being micturition urgency, occurring in 2 patients. No grade 4-5 events occurred. Although these results demonstrated the treatment efficacy of nadofaragene firadenovec and the need for further research on this agent, this study was limited because there was no central pathology review and initial responses were gauged by cystoscopy and cytology reports, which are contingent upon the experience and criteria utilized by the individual pathologist (74).

**FUTURE PERSPECTIVES FOR BLADDER CANCER TREATMENT**

There are multiple phase I and phase II trials (ongoing or recently completed) and ongoing phase III trials studying diverse therapies for both advanced or metastatic bladder cancer and NMIBC. The trials and the studied agents are listed in Table 2.

### Phase I and II Trials for Advanced/Metastatic UC Treatment

#### Immunotherapy

PD-1/PD-L1 and CTLA-4 inhibitors continue to be investigated for advanced/metastatic UC therapy. Toripalimab is a humanized antibody targeting PD-1, was studied in a phase I trial published in 2019 and showed promising results. 36 patients with either advanced UC, renal cell carcinoma (RCC), or melanoma resistant to first-line therapy were given toripalimab, with an average of 12.4 doses. The therapy was well-tolerated, with most of the treatment related adverse events being grade 1 or 2. The most common grade 3-4 AEs were elevated lipase and anemia (75).

In an ongoing phase II trial, nivolumab is being studied as preoperative therapy concomitantly with radiation, in patients with locally advanced bladder cancer who then undergo radical cystectomy with lymphadenectomy (NCT03529890). Nivolumab 240 mg will be administered for a total of 4 cycles, every 2 weeks, with concomitant radiation therapy. The primary endpoint will be the rate of patients who completed the regimen (radiation with nivolumab, followed by radical cystectomy) after week 15 (76).

Tremelimumab is an CTLA-4 inhibitor that can potentially contribute to UC management. There is an ongoing phase II trial comparing tremelimumab monotherapy, durvalumab monotherapy, and durvalumab and tremelimumab combination therapy for advanced solid tumors, including UC. The most recent results update show that there was a 6.2% complete response rate in the advanced UC arm. Out of 32 UC patients, 18 had severe adverse events, with diarrhea and colitis being the most common (NCT02527434).

Another phase Ib/II study in the recruitment phase will compare the outcomes of various immunotherapy-based treatment combinations in patients with locally advanced or metastatic UC, involving drugs such as EV and atezolizumab (NCT03869190).

Enoblituzumab is a monoclonal antibody that targets B7-H3, a checkpoint protein that promotes tumor proliferation and regulates the metabolic activity of cancer cells. It is being studied in a phase I trial for patients with refractory cancer, including malignancies such as bladder cancer (NCT01391143).

Tislelizumab is a PD-1 monoclonal antibody that is currently being studied in a phase II trial, involving patients with advanced or metastatic UC who had progressed after platinum-based chemotherapy (NCT04004221).

**Targeting FGFR**

Rogaratinib is another oral pan FGFR inhibitor that was studied in a phase I trial involving patients with various advanced malignancies, including UC. Out of the 126 patients treated, 52 of them were UC patients whose malignancy overexpressed the mRNA for FGFR. The agent was well-tolerated, and 15% of the patients in the expansion cohorts achieved an objective response. The most common treatment-related AEs were hyperphosphatemia [77 (61%) out of 126 patients] and diarrhea [65(52%)] (77).
| Novel Agent | Primary Mechanism          | UC Population Treated | Trial Phase | Study/Trial #        |
|-------------|---------------------------|-----------------------|-------------|----------------------|
| Toripalimab | PD-1 antibody             | Advanced UC           | I           | Tang et al. (75)     |
| Nivolumab concomitant radiation | PD-1 antibody | Advanced UC that will undergo cystectomy | II | Schmid et al. (76) |
| Tremelimumab | CTLA-4 antibody + PD-1 antibody | Advanced UC | II | NCT02527434 |
| Durvalumab | Antibody-drug conjugate + PD-L1 ligand | Advanced/metastatic UC | II/II | NCT03869190 |
| Enfortumab vedotin | Antibody-drug conjugate + PD-L1 ligand | Advanced/metastatic UC (cisplatin ineligible) | II | NCT03472560 |
| Atezolizumab | B7-H3 antibody | Refractory UC | I | NCT01391143 |
| Tislelizumab | PD-1 antibody | Advanced/metastatic UC | II | NCT04004221 |
| Rogaratinib | Pan-FGFR inhibitor | Advanced UC | I | Schuler et al. (77) |
| Derazantanib | Pan-FGFR inhibitor | Advanced UC | I | NCT01967641 |
| Infracitinib | Pan-FGFR inhibitor | Advanced UC | I | Papadopoulos (78) |
| Carotuximab | Endoglin antibody | Advanced/metastatic UC | II | Apollo et al. (79) |
| Axitinib | VEGFR inhibitor | Advanced/metastatic UC | I | NCT01004224 |
| + | PD-L1 antibody | UC | | |
| Ramucirumab | VEGFR inhibitor | Advanced UC refractory to prior therapy | I | Choukhury et al. (82) |
| Tisotumab vedotin | Antibody-drug conjugate | Advanced/metastatic UC | I/I/II | NCT02675829 |
| Adu-trastuzumab | Antibody-drug conjugate | Advanced UC | | |
| Afatinib | EGFR/HER2 inhibitor | Metastatic UC after platinum failure | II | Bellmunt et al. (83) |
| Genestein | EGFR inhibitor | Advanced UC that will undergo cystectomy or TURBT | II | NCT00118040 |
| Everolimus | mTOR inhibitor | Metastatic UC progressing after 1-4 cytotoxic agents | | |
| Temsirolimus | mTOR inhibitor | Metastatic UC after platinum failure | II | Seront et al. (83) |
| Cabozantinib | Multi-kinase inhibitor | Metastatic UC refractory to platinum | II | Milowsky et al. (84) |
| Sorafenib | Multi-kinase inhibitor | Metastatic UC that progressed after platinum | I | Apollo et al. (85) |
| Pazopanib | Multi-kinase inhibitor | Metastatic UC ineligible for platinum or progressed after platinum | I | Shah et al. (86) |
| | mTOR inhibitor | UC | | |
| Everolimus | Multi-kinase inhibitor | Metastatic UC that progressed after platinum | II | NCT02459119 |
| Merestinib | Multi-kinase inhibitor | Advanced/metastatic UC | I | NCT03207284 |
| Selumetinib | Multi-kinase inhibitor | Advanced/metastatic UC that progressed with prior therapy | I | NCT02546661 |
| Vistusertib | MTOR inhibitor | Metastatic UC | I | Siefker-Radke et al. (89) |
| AZD4547 | FGFR 1/2/3 inhibitor | Advanced UC that relapsed after platinum | II | Rosenberg et al. (90) |
| Olaparib | PARP inhibitor | UC | | |
| Durvalumab | PD-L1 inhibitor | UC | | |
| SGT-95 | R894 plasmid | Metastatic UC with no available standard therapy | I | Kang et al. (91) |
| Docetaxel | Microtubule inhibitor + Hsp27 inhibitor | UC | | |
| Apatersen | Microtubule inhibitor | Advanced UC that progressed after cisplatin | | |
| Paclitaxel | Microtubule inhibitor | Advanced UC after platinum and pembrolizumab failed | | |
| Cabazitaxel | Microtubule inhibitor | Metastatic UC eligible for cystectomy | | |
| Pemetrexed | Folate antimetabolite | Advanced UC resistant to platinum | N/A | Chaliana et al. (94) |
| | | Advanced UC | | |
| | | Advanced/metastatic UC | | |
| | | Metastatic UC refractory to platinum | | |
| | | Advanced, untreated UC | | |
| | | Advanced UC | | |
| Apatersen | Hsp27 inhibitor | UC | | |
| Pralatrexate | DHFR inhibitor | UC | | |
| Palbociclib | CDK 4/6 inhibitor | UC | | |
| Fluorocyclo-pentenyl cytosine | Cytidine analog and methyltransferase inhibitor | Advanced UC | I | Adashkev et al. (101), NCT0230067 |

(Continued)
A recent completed phase I study involving 168 patients with metastatic or advanced malignancies such as UC also found that rogaritinib has a manageable safety profile in this population (NCT01976741).

The pan FGFR inhibitor derazantinib (ARQ 087) may also have a promising role in advanced UC treatment. The first human study involving derazantinib was published in 2017, and this phase I trial had a manageable safety profile in patients with advanced metastatic UC.
solid tumors. The most common treatment-related AEs were fatigue, nausea, and increased AST. 14 out of 80 patients (18%) experienced AEs grade ≥3.

Infigratinib (BGJ398) is a pan-FGFR inhibitor that is being studied in bladder cancer patients. There are ongoing phase I dose escalation study examining the safety and effects of infigratinib in patients with advanced solid malignancies including UC (NCT01004224).

Targeting Angiogenesis

Multiple trials are investigating agents targeting the angiogenesis pathway. Carotuximab (TRC105) is a monoclonal antibody that binds to endoglin (CD105), a membrane glycoprotein that is part of the TGF beta receptor, which helps regulate angiogenesis. A phase II trial administered TRC105 to patients with previously treated advanced UC, and found that, although well-tolerated, TRC105 did not improve 6-month survival in these patients. The group’s 3-month PFS probability was 18.2%, with a median OS of 8.3 months. Among the 13 patients enrolled, the most common AEs were headache (9[69%]) and infusion-related reactions (9[69%]). Only 2 patients experienced grade ≥3 AEs (79).

Axitinib inhibits VEGF receptors 1-3, and is being studied as combination therapy with avelumab in a phase 2 trial for patients with NSCLC who have received at least one platinum-containing therapy previously and patients with treatment naïve or metastatic/advanced UC who are ineligible for cisplatin. The primary outcome will be objective response based on RECIST version 1.1 criteria, and the predicted completion date is June 2022 (NCT03472560).

Ramucirumab is a VEGFR-2 antagonist, disrupting the angiogenesis pathway regulated by VEGF in tumor cells. A phase la/b trial studied the safety of ramucirumab with pembrozumab therapy for patients with advanced gastroesophageal adenocarcinoma, NSCLC, or UC refractory to prior treatment. The study concluded that this combination therapy had a manageable safety profile; out of 92 patients, 22 patients had grade ≥3 treatment-related adverse events, with hypertension occurring in 6 patients and colitis occurring in 5 (80).

Antibody-Drug Conjugates

Tisotumab vedotin is an antibody-drug conjugate that targets tissue factor, which is expressed on most solid malignancies. A phase I/II study involving 147 patients with either relapsed or advanced/metastatic malignancies, including UC, found that tisotumab vedotin treatment produced an ORR of 15.6%, and 27% experienced rate of severe AEs, the most common grade ≥3 AEs being fatigue (14[10%]), anemia (8[5%]), abdominal pain (6[4%]), and hypokalemia (6[4%]) (81).

Ado-trastuzumab emtansine is an antibody-drug conjugate that allows trastuzumab, which binds to HER2 receptors, to be internalized by tumor cells. An ongoing phase II trial will assess the best overall response over a period of 2 years in patients with HER-2 mutant or amplified malignancies, including UC (NCT02675829).

Targeting EGFR, HER Pathways

Afatinib inhibits the EGFR, HER-2 and HER-4 tyrosine kinases. A phase II trial administered afatinib to 23 patients with metastatic UC refractory to platinum therapy. 5 (21.7%) patients achieved partial response or stable disease, and the median time before progression was 6.6 months in patients with HER2 amplifications or EGFR mutations. Out of the 23 patients, the most common grade 3 AEs were nausea and vomiting, diarrhea, aceniform rash, and fatigue (82). There is a phase II trial currently in the recruitment phase that will measure the 3-month PFS rate in patients with metastatic UC refractory to platinum therapy after receiving afatinib (NCT02122172). Another phase II trial will measure the 6-month PFS in advanced or metastatic UC patients who have failed platinum therapy and have HER-2, HER-3, or EGFR genetic alterations (NCT02780687).

Another phase II randomized, double arm trial is studying the phosphorylation activity of Genestein (G-2535) on EGF receptors in stage I to stage III non-invasive and invasive bladder cancer patients. Multiple tissue biomarkers will be compared between the placebo, high dose G-2535, and low dose G-2535 groups (NCT00118040).

Targeting the mTOR Pathway

There is also growing research supporting the use of agents targeting PI3K/AKT/mTOR, a signaling pathway which regulates tumor proliferation, for localized UC therapy. Everolimus is an oral mTOR inhibitor that has demonstrated clinical benefit in advanced/metastatic UC. Seront et al.’s 2012 phase II trial enrolled 37 patients with advanced UC that had failed platinum chemotherapy. 2 patients had partial response, and 8 achieved stable disease, with a disease control rate of 27% after 8 weeks. The most common grade 3-4 AEs were fatigue [10 (27%)] and thrombopenia [5(13%)] (83). Additionally, Milowsky et al.’s 2013 phase II trial administered everolimus to 45 patients with metastatic UC that progressed after receiving cytotoxic therapy. After 2 months, 23 (51%) patients were progression free, the median PFS was 2.6 months and median OS was 8.3 months (95% CI). The most common grade 3-4 AEs included anemia [9(20%)], abnormal INR [7(16%)], and infection [6 (13%)] (84).

Temsirolimus is an mTOR inhibitor that is being considered as potential second-line therapy for UC. A phase II trial evaluated patients with recurrent or metastatic bladder cancer treated with temsirolimus. The median PFS was 2.8 months and OS was 7.2 months. However, 50 of 53 patients experienced grade 1 or 2 treatment related toxicity, and 28 patients had a grade 3 or 4 adverse event, so this high risk of adverse events must be weighed carefully against its therapeutic impact. The most common grade 3-4 AEs were hematologic toxicity [10 (18.9%)], asthenia/fatigue [10(18.9%)], and gastrointestinal toxicity [6(11.3%)] (85).

Kinase Inhibitors

Kinase inhibitors can bind to multiple tumor cell receptors and thereby inhibit major proliferation pathways. Cabozantinib inhibits multiple receptor tyrosine kinases such as VEGF, RET, AXL, and MET, which regulate signaling cascades involved in tumor proliferation. In a phase II trial involving patients with metastatic UC refractory to platinum-based
therapy, cabozantinib was well-tolerated and produced an ORR of 19%. Among 68 patients, the most common grade 3-4 AEs were fatigue [6(9%)], hypertension [5(7%)], proteinuria [4(6%)], and hypophosphatemia [4(6%)] (86).

Sorafenib is another multi-kinase inhibitor, targeting VEGFR, PDGFR, and many RAF kinases, whose safety and efficacy have been assessed in UC patients. A phase I trial administered sorafenib with vinflunine therapy to patients with metastatic UC that progressed following platinum-based chemotherapy. The median OS was 7.0 months, and the ORR was 41%. The most frequent grade 3-4 AEs were neutropenia (6 of 22 patients), febrile neutropenia (5), and hyponatremia (5) (87).

Additionally, a 2018 phase I trial studied the effects of everolimus with the tyrosine kinase inhibitor pazopanib in 19 metastatic UC patients, 3 NSCLC patients, and 1 adenocortical carcinoma patient (all of whom had previously received their respective standard therapies, followed by disease progression) and produced promising results. The ORR was 21%, and 73.7% of patients experienced a grade 3 or higher treatment related toxicity. The most frequent grade 3-4 treatment-related AEs were fatigue, elevated AST, thrombocytopenia and hypophosphatemia (88).

The multi-kinase inhibitor regorafenib, which especially targets kinases involved in angiogenesis, was studied in a phase II trial for 17 patients with progressive, metastatic UC. The primary outcome, 6-month PFS, was 17.6%. Grade 3 AEs included diarrhea, fatigue, low phosphorous levels, anemia and thrombocytopenia (NCT02459119).

Merestinib inhibits multiple tyrosine kinases, including c-MET, which has high activity in multiple malignancies. A phase I trial is comparing the safety of merestinib monotherapy to merestinib combined with cisplatin and gemcitabine for advanced or metastatic malignancies such as UC (NCT03027284).

There is an ongoing phase Ib trial examining the safety of multiple unique agents for the treatment of MIBC that progressed following standard treatment. These agents include the multitkinese inhibitor selumetinib, the mTOR inhibitor vistusertib, the PARP inhibitor Olaparib, the FGFR 1/2/3 inhibitor AZD4547, and the tyrosine kinase inhibitor adavosertib, which targets Wee1, a cell cycle regulator that phosphorylates Cdk1 (NCT02546661).

Gene Therapy
Gene therapy can safely produce toxic effects on bladder cancer cells. SGT-94 carries a plasmid that encodes the truncated version of the retinoblastoma gene, which promotes tumor suppression. A phase I trial showed that SGT-94 was safe in patients with metastatic genitourinary cancers that had no available standard therapy, and did not affect normal urothelial cells. Only 2 patients experienced grade 3-4 adverse events (lymphopenia and neutropenia) (89).

DNA Replication/Repair/Gene Expression/Protein Synthesis Inhibition and Taxanes
A handful of therapies under recent investigation for advanced UC treatment are those targeting DNA synthesis, repair, and gene expression. Taxanes disrupt cell division by inhibiting microtubule function. In addition to the previously discussed 2017 phase III trial that demonstrated the efficacy of docetaxel in combination with ramucirumab (70), as well as the 2018 phase II study that showed improved outcomes in UC patients given docetaxel plus apatinib compared to docetaxel monotherapy (90), paclitaxel has also shown promise as second or third-line combination therapy with cytotoxic chemotherapy and other agents. A 2020 phase II single-arm trial administered paclitaxel, gemcitabine and cisplatin to twenty-one patients with advanced/metastatic UC that progressed after platinum-based chemotherapy. The ORR was 23.8%, and the respective median PFS and OS were 4 and 8.4 months. 71.4% and 42.9% of patients experienced grade 3-4 neutropenia and thrombocytopenia, respectively (91). In the first report that specifically examined paclitaxel with carboplatin therapy for advanced UC patients after platinum-based chemotherapy and pembrolizumab failed, the median PFS and median OS were 9.8 months and 13.0 months, respectively (92). Paclitaxel with ifosfamide and nedaplatin is another potential second-line treatment option. A retrospective study published in 2016 examined 33 patients with metastatic UC who were given this regimen after cisplatin-based therapy failed. The median OS was 10.4 months, the median PFS was 3.5 months and the ORR was 30%. There were no treatment-related deaths, although all patients acquired grade 3-4 neutropenia (93).

The taxane cabazitaxel has been studied as combination therapy with cisplatin in a phase II trial for MIBC patients who are eligible for radical cystectomy. The most common treatment-related AEs were fatigue and nausea and vomiting. Among 26 patients, the ORR was 57.7% (95% CI 36.9%-76.6%). Only 10 patients experienced grade ≥3 AEs (94).

Pemetrexed inhibits multiple folate-dependent enzymes, thereby limiting cancer growth by inhibiting nucleotide synthesis, and has been studied in a handful of trials since 2015. A retrospective analysis also examined the efficacy of pemetrexed as monotherapy in 129 platinum-resistant advanced UC patients. The ORR was 5% and median PFS was 2.4 months (95). Pemetrexed has also been used as combination therapy with various agents. The phase II PECULIAR study involved 42 advanced UC patients, treated with pemetrexed and cisplatin combination therapy; the ORR was 64.3%, median PFS was 6.9 months, and median OS was 14.4 months. 33.33% of the patients experienced grade 3-4 neutropenia (96). Cao et al.’s phase I 2018 trial compared the outcomes of gemcitabine-cisplatin versus pemetrexed-cisplatin in patients with advanced or metastatic UC. The gemcitabine-cisplatin group had response rate of 68% and disease control of 86%, compared to the pemetrexed-cisplatin group’s significantly lower response rate and disease control of 44% and 56%, respectively (97). A phase I trial studying pemetrexed with vinflunine in patients with metastatic UC refractory to platinum chemotherapy suggested that this regimen has poor outcomes. Out of the four patients enrolled in the study, one patient had grade 4 thrombocytopenia, another patient had grade 3 hepatobiliary toxicity, and all patients had progression as defined by RECIST 1.1 criteria (98).

Apatorsen is an antisense oligonucleotide that inhibits heat shock protein 27. In the 2017 phase II Borealis-1 trial, patients...
with advanced, untreated UC were randomly assigned to receive GC with placebo, 600 mg apatorsen, or with 1000 mg apatorsen. Overall survival was the primary endpoint. There was not a significant survival benefit in patients treated with the combination of GC with 600 mg or 1000 mg apatorsen; however, exploratory analysis showed a trend for improved survival in patients with poor prognostic features (99). The 2018 Borealis-2 trial was a phase II study that examined treatment outcomes when apatorsen was given with the microtubule inhibitor docetaxel in patients with metastatic UC who relapsed after given platinum-based chemotherapy. Patients who received apatorsen with docetaxel had significantly improved OS compared to those who received docetaxel alone, with a median OS of 6.4 versus 5.9 months. In the apatorsen with docetaxel group, common grade 3-5 AEs were leukopenia [27 (29%)], neutropenia [33(35%)], anemia [16(17%)], and sepsis [14(15.1%)] (90).

Pralatrexate (PTX) is a new agent that inhibits dihydrofolate reductase (DHFR), and palbociclib isethionate (PAL) is a cell cycle inhibitor evaluated in colon cancer, lung cancer, and HER2-+ ER+ breast cancer. Wang et al.’s retrospective analysis studied the clinical efficacy of PTX with PAL in advanced bladder cancer patients. 42 cases involved PTX + PAL therapy, and 40 cases received GC. In the PTX + PAL group, 33.33% achieved CR and had significantly lower rates of adverse events such as nausea, vomiting and liver function enzyme elevation compared to the GC group. The most common treatment-related AEs in the PTX + PAL group was leukopenia [19(45.2%)] and nausea and vomiting [15(35.7%)] (100).

Another novel agent, fluorocyclopentenyl cytosine (RX-3117), is activated exclusively in the tumor environment and acts by damaging DNA and inhibiting DNA methyltransferase 1, and studies have demonstrated its efficacy for the treatment of pancreatic cancer and advanced UC (117). There is an ongoing phase 2a study involving RX-3117 monotherapy for advanced UC (NCT02030067). The preliminary results suggest that RX-3117 is well-tolerated and able to induce partial response and tumor reduction, with fatigue, diarrhea and nausea and vomiting being the most common AEs (101).

Olaparib inhibits poly ADP ribose polymerase, a DNA repair enzyme, restricting DNA replication in tumor cells. Olaparib is being studied in a phase II trial as combination therapy with durvalumab for patients with unresectable stage IV UC who are ineligible for platinum therapy, and the outcomes will be compared to treatment with durvalumab monotherapy (NCT03459846). Another ongoing phase II trial is studying the effects of neoadjuvant olaparib with durvalumab in patients with resectable stage IV UC prior to surgery (NCT03534492). The preliminary data showed a pathologic CRR of 44.5% with only 8.3% of patients experiencing a grade 3 or 4 AE. Common AEs from this combination therapy include grade 1 nausea and vomiting and anemia (102).

5-fluoro-2'-deoxycytidine (FdCyd) alters gene expression in cancer cells, and tetrahydrouridine (THU) prevents FdCyd breakdown. The safety and antitumor effects of FdCyd with THU in patients with unresectable or metastatic malignancies such as UC that progressed after standard therapy are currently being studied in a phase II trial (NCT00978250).

**T-Cell Therapies**

There is a phase I study investigating chimeric antigen receptor T-cell (CAR-T) therapy for refractory or recurrent stage IV solid malignancies such as bladder cancer. CAR-T therapy utilizes genetic engineering to create specific T-cell receptors that will enable the host immune response to recognize tumor cells. Patients who have a biopsy positive for receptor tyrosine kinase-like orphan receptor 2 will receive this treatment (NCT03960060). CAR-T has proven itself to be promising therapy for B cell malignancies, but its efficacy as treatment for solid tumors has yet to be demonstrated. This is due to the significant challenges to immune function presented by the solid tumor setting, such as limited capacity for lymphocyte invasion, which are not found in the environment of hematologic malignancies (118).

Another ongoing phase I study compares the effects of PF-04518600, an agonist of the memory T-cell protein OX40 (CD134), as monotherapy versus combination therapy with utomilumab (PF-05082566), an agonist of the 4-1BB (CD-137) receptor on T cells and natural killer cells, in patients with advanced or metastatic malignancies including UC (NCT02315066).

An ongoing phase I trial is examining the safety profile of TCR affinity enhancing specific T cell therapy (TAEST16001) for advanced solid tumors such as bladder cancer that failed multiline treatment. To be eligible for enrollment, patients must have cells that are HLA-A*0201 positive and at least 25% of cells must be NY-ESO-1 positive (NCT03159585).

There is also a phase II trial studying cytokine induced killer cells for management of bladder neoplasms after chemotherapy treatment; this study will enroll about 1500 patients with stage I-III bladder cancer (NCT02489890).

**Personal Peptide and Virus Vaccinations**

There is rapidly growing literature on utilizing cancer peptide vaccinations (PPV) for management of bladder cancer. PPV customizes therapy for a specific individual by accounting for a patient’s HLA markers and host immunity prior to vaccination. The antigens presented by peptide vaccines can trigger specific T-cell responses against tumor activity. S-288310 contains two distinct kinds of peptide vaccines, one derived from M phase phosphoprotein 1 (MPHOSPH1) and one derived from DEP domain containing 1 (DEPDC1), and was shown in a phase I/II study to be safe and effectively induced cytotoxic T-lymphocytes in advanced UC patients. The ORR was 6.3% in 32 patients. After one, two, and three or more regimens, the median OS rates were 14.4, 9.1 and 3.7 months respectively (103). Another phase II trial compared PPV monotherapy to PPV plus salvage chemotherapy in metastatic/advanced upper tract UC patients who had failed platinum-based chemotherapy. The combination therapy group’s median survival time was 13.0 months and there were no severe adverse treatment-related events (104). A phase II randomized trial compared the outcomes of PPV with best supportive care (BSC) versus PPV alone in UC patients who...
progressed after platinum-based therapy. There was no significant improvement in PFS, but the median OS was 7.9 months in the PPV with BSC group compared to 4.1 months in the BSC alone group, and PPV therapy was well-tolerated. The most common AE was dermatologic reactions at the sites of injection, abdominal pain, peripheral edema, and anemia, but no immune-mediated severe AEs were observed (105).

NEO-PV-01 is a new type of PPV that is specifically designed based on a particular individual’s tumor DNA and can administer up to twenty customized peptides in each dose. It is administered with the adjuvant Poly-ICLC, which helps to stimulate the immune response. An ongoing phase I trial is studying the effects of NEO-PV-01 plus Poly-ICLC in combination with nivolumab for patients with advanced/metastatic melanoma, NSCLC, or UC (NCT02897765).

The modified vaccinia Ankara virus, an attenuated poxvirus vaccine, can potentially improve the host immune response to UC antigens. It is currently being studied in a phase I trial as combination therapy with pembrolizumab in patients with refractory metastatic malignancies including UC that are overexpressing p53 (NCT02432963).

Oncolytic Virus Therapy

The oncolytic virus CAVATAK is being studied in another phase I trial as combination therapy with pembrolizumab for patients with either advanced/metastatic NSCLC, melanoma, prostate cancer or UC (NCT02043665).

Agents Altering Tumor Microenvironment

Another pathway that is being investigated is the IDO1 mediated immune mechanism. IDO1 is a cytosolic enzyme that changes the tumor microenvironment so that there are greater amounts of kynurenine and lower tryptophan levels; this promotes the activity of T regulator cells and inhibits effector T cells. Navoximod is a small molecule that inhibits IDO1. Jung et al.’s phase Ib trial examined the safety of combination therapy with navoximod and atezolizumab in advanced/metastatic solid tumors including urothelial carcinoma. 158 patients were enrolled, and the study involved a dose escalation and an expansion stage. Adverse effects reporting period continued until 60 days after the final dose of navoximod and/or atezolizumab. 22% of patients experienced treatment related adverse effects of grade 3 or higher, the most common being rash (14.9%) (106).

NCB024360 (epacadostat) is another IDO1 inhibitor whose safety and efficacy have been recently studied in a phase I/II when given in combination with pembrolizumab for malignancies including advanced bladder cancer. For the highest dose of NCB024360 given in phase I (300 mg BID), 8 of 20 participants experienced serious adverse effects. In phase II, patients were given 100 mg BID and the all-cause mortality rate was 53.14%. The most common grade ≥3 treatment-related AE was rash (NCT02178722).

Arginase depletes the tumor environment of arginine, leading to suppressed function of the immune cells. Thus, arginase inhibition can restore the host immune defense against tumor cells. The arginase inhibitor INCB001158 is currently being studied in a phase I/II trial for patients with advanced/metastatic malignancies such as UC. Patient outcomes from INCB001158 monotherapy will be compared to the outcomes produced by INCB001158 combined with pembrolizumab (NCT02903914).

Future Perspectives for NMIBC

DNA Synthesis, Replication

The anthracycline agent pirarubicin has been studied as combination treatment with hyaluronic acid following TURBT. Huang et al.’s 2015 trial has suggested that this combination therapy is safe and more tolerable than pirarubicin alone in NMIBC patients after TURBT. There was no statistically significant difference in recurrence between the combination therapy group and the pirarubicin only group (18.8% vs. 25.4%, P = 0.27). The most common treatment-related AEs in both groups were odynuria, cystitis and anxiety, but no severe AEs occurred in either arm (107).

Cabazitaxel in combination with gemcitabine and cisplatin administered as intravesical therapy has also shown in a phase I study to be a well-tolerated regimen in patients with NMIBC that failed intravesical BCG therapy. The initial partial rate was 94%, and the ORR was 89%. The 1-year recurrence free survival was 0.83, with a 2-year estimated RFS of 0.64. There were no dose-limiting toxicities (108).

Apaziquone (Qapzola) is an analog of mitomycin C, a crosslinking agent that inhibits DNA synthesis. It is being studied as adjuvant therapy in NMIBC patients; two phase III trials are currently examining the efficacy of apaziquone in NMIBC patients after TURBT. One trial compares an 8 mg apaziquone treatment group to a placebo group (NCT03224182), and the other compares 4 mg apaziquone versus 8 mg apaziquone treatment groups relative to a placebo group (NCT02563561).

Vicinium contains a recombinant fusion protein called that VB4-845, which binds to the epithelial cell adhesion molecule antigen that is on the surface of cancer cells. Once internalized, this protein can block protein synthesis, thereby inducing cell death. A Phase III trial is currently studying the efficacy of Vicinium for NMIBC in situ or high-grade invasive papillary bladder cancer who have failed BCG therapy (NCT02449239).

Dendritic cell-based immunotherapy has also been proposed as a feasible regimen in advanced UC patients. Dendritic cells (DC) are a type of antigen presenting cells that can trigger both the innate and adaptive immune response. Ogasawara et al.’s phase I/II trial examined vaccination therapy involving Wilms Tumor 1 peptide-pulsed dendritic cells and OK-432 in combination with molecular targeted therapy or standard chemotherapy. Five renal cell carcinoma and five NMIBC patients were enrolled. The dendritic cells and OK-432 were administered as intravesical therapy has also shown in a phase I study to be a well-tolerated regimen in patients with NMIBC that failed intravesical BCG therapy. The initial partial rate was 94%, and the ORR was 89%. The 1-year recurrence free survival was 0.83, with a 2-year estimated RFS of 0.64. There were no dose-limiting toxicities (108).

Apaziquone (Qapzola) is an analog of mitomycin C, a crosslinking agent that inhibits DNA synthesis. It is being studied as adjuvant therapy in NMIBC patients; two phase III trials are currently examining the efficacy of apaziquone in NMIBC patients after TURBT. One trial compares an 8 mg apaziquone treatment group to a placebo group (NCT03224182), and the other compares 4 mg apaziquone versus 8 mg apaziquone treatment groups relative to a placebo group (NCT02563561).

Vicinium contains a recombinant fusion protein called that VB4-845, which binds to the epithelial cell adhesion molecule antigen that is on the surface of cancer cells. Once internalized, this protein can block protein synthesis, thereby inducing cell death. A Phase III trial is currently studying the efficacy of Vicinium for NMIBC in situ or high-grade invasive papillary bladder cancer who have failed BCG therapy (NCT02449239).

Dendritic cell-based immunotherapy has also been proposed as a feasible regimen in advanced UC patients. Dendritic cells (DC) are a type of antigen presenting cells that can trigger both the innate and adaptive immune response. Ogasawara et al.’s phase I/II trial examined vaccination therapy involving Wilms Tumor 1 peptide-pulsed dendritic cells and OK-432 in combination with molecular targeted therapy or standard chemotherapy. Five renal cell carcinoma and five NMIBC patients were enrolled. The dendritic cells and OK-432 were given every two weeks, with seven doses total. Salvage chemotherapy was provided as adjuvant treatment in UC patients. None of the patients had adverse events from the leukapheresis period. Other than grade 3 hematological adverse effects that occurred in 5 patients, all patients’ treatment related adverse effects were grade 1 or 2. The two patients with metastatic UC died following DC vaccination, but three of the
NMIBC patients achieved stable disease. Only 4 patients experienced grade 3 AEs, all of which were hematologic (leukocytopenia, neutropenia, anemia) (109).

**Oncolytic Viruses**

A phase I trial studied CAVATAK, a coxsackievirus agent that targets ICAM-1 in NMIBC patients scheduled for TURBT. By binding to adhesion molecules like ICAM-1, the virus can enter and subsequently lyse tumor cells. A phase I trial administered CAVATAK to NMIBC patients; 9 patients received CAVATAK alone and 6 received it after first being treated with mitomycin C. The safety profile was manageable, with only 1 patient who received CAVATAK alone experiencing a serious adverse effect. Tissue biopsies also demonstrated that CAVATAK upregulated immune checkpoint inhibitory genes such as PD-L1 and LAG3 and chemokines associated with Th1. Common AEs included asthenia, chills, neutropenia, and pyrexia, but no grade 3-4 AEs occurred (111).

CG0070 is another oncolytic adenovirus, which specifically targets UC cells. Its mechanism of action involves triggering the lysis of cancer cells and releasing various antigens that lead to a widespread anti-tumor host response. The interim findings of a phase II study that administered CG0070 to NMIBC patients refractory to intravesical BCG therapy and refused cystectomy (NCT02365818) showed that the 6-month CR among all 45 patients was 47%, with a manageable toxicity level. The most common treatment-related AEs were bladder spasms, hematuria, tenderness, urological symptoms, and systemic symptoms, but BCG treatment did not exacerbate these AEs (113).

**Virus Vector Vaccine**

PANVAC is a virus vector that contains the CEA and MUC-1 genes, which are commonly found in solid malignancies, and costimulatory molecules to improve host T-cell response. A phase I trial compared PANVAC alone with PANVAC plus BCG therapy for patients with high-grade NMIBC who had previously failed at least one course of intravesical BCG therapy. The 6-month RFS was 66% in the PANVAC plus BCG group, compared to 60% in the PANVAC alone group. In the combination therapy group, the all-cause mortality was 20% (3 patients out of 15), versus 13.33% in the PANVAC monotherapy group (2 of 15). Serious AEs in the combination therapy arm include postoperative hemorrhage, hematuria, urinary retention, and urinary tract obstruction (NCT02015104).

**Personal Peptide Vaccination**

Peptide vaccines have also been studied as therapy for NMIBC. In non-muscle invasive UC, a phase II trial researched both MPHOSPH1 and DEPDC1 for prevention of NMIBC recurrence after undergoing TURBT. Recurrence free survival (RFS) was 74%, and was longer in patients who had a positive reaction to at least one peptide vaccine in combination with the BCG vaccine (p = 0.0019). Out of 132 patients, only 2 experienced a grade 3 event. The most common grade 1-2 AEs were urinary frequency, hematuria, and urinary tract pain (112).

**MAGE-A3 Vaccine**

The results of a phase I trial suggest that the melanoma-associated antigen (MAGE-A3) tumor vaccine, when combined with BCG is a safe regimen for NMIBC that does not disrupt the function of BCG. Following intravesical BCG and vaccine administration, the most common AEs were local injection site tenderness, urological symptoms and systemic symptoms, but BCG treatment did not exacerbate these AEs (113).

**Targeting FGFR**

There is an ongoing study involving 4 patients with NMIBC treated with the pan-FGFR inhibitor infritinib, and cystoscopy and cytology will be used to assess tumor response (NCT02657486).

**Targeting the mTOR Pathway**

Rapamycin, also known as sirolimus, is a macrolide agent that inhibits both the mTORC1 and mTORC2 complexes and thus limits cancer proliferation through multiple mechanisms (120). There is an ongoing combined phase I/II trial that examines role of albumin-bound rapamycin nanoparticles in patients with recurrent NMIBC or muscle-invasive bladder cancer that is refractory to BCG therapy (NCT02009332). There is also a phase II trial in the recruitment process investigating encapsulated rapamycin as a secondary prevention agent for NMIBC (NCT04375813).

**Angiogenesis**

APL-1202 is a methionine aminopeptidase type II inhibitor, limiting angiogenesis by inhibiting the proliferation of endothelial cells. It is being currently being studied in a phase Ib trial in NMIBC patients resistant to one induction course of BCG. The safety of APL-1202 monotherapy will be assessed and compared to the outcomes of patients that received APL-1202 with concurrent BCG (NCT03672240).

**Nadofaragene Firadenovec**

The gene transfer vector nadofaragene firadenovec has been studied as therapy for not only advanced/metastatic UC, but NMIBC as well. A phase II study involving patients with relapsed or BCG refractory NMIBC were given intravesical nadofaragene firadenovec. Out of 40 patients, 14 remained recurrence-free for 12 months after receiving treatment, and the therapy was well-tolerated. The most common treatment-related AEs were micturition urgency (16[40%]), dysuria (16[40%]), and
fatigue (13[32.5%]) (114). There is an ongoing phase III study evaluating this agent in patients with high grade NMIBC refractory to intravesicular BCG therapy, and CR rate will be assessed (NCT02773849).

**Immunomodulators**

Imiquimod is a toll-like receptor 7 agonist that regulates various functions including cytokine release, angiogenesis, and immune cell proliferation. Although it is typically used as topical treatment for skin malignancies, and has a liquid formulation called TMX-101 (Vesimune) that has been safely used in a phase I trial involving non-muscle invasive bladder cancer patients (115). A phase II trial involving 12 UC in situ patients were treated with 6 weekly intravesical doses of TMX-101, and half of these patients received at least 2 induction courses of BCG. Only 1 patient experienced a treatment related adverse event greater than grade 2 (urinary tract infection), and 2 patients had a clinical response. Additionally, there were significant elevations in urinary levels of various interleukins and VEGF after treatment (116).

**CONCLUSION**

Pioneering research in the management of bladder cancer over the past decade has introduced a surge of new therapeutic agents with various novel molecular targets through rapidly advancing technology. These therapies have revolutionized the field of urothelial cancer and provide feasible alternatives to traditional platinum-based chemotherapy regimens. Many of these agents are still in the early phases of investigation to examine safety and efficacy. Although a handful of agents have received FDA approval and have shown significant promise, more research is required to identify additional targets, fully elucidate their molecular mechanisms, and determine their long-term outcomes.

**AUTHOR CONTRIBUTIONS**

BN and AH: Conceptualization, Methodology, Data curation, Original draft preparation & Illustration. BJ: Conceptualization, Reviewing and Editing. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

We would like to thank the University of Texas Medical Branch Library with assistance with research materials for this manuscript.

**REFERENCES**

1. Richters A, Aben KKH, Kiemeney LALM. The Global Burden of Urinary Bladder Cancer: An Update. *World J Urol* (2020) 38(8):1895–904. doi: 10.1007/s00345-019-02984-4
2. Lenis AT, Lee PM, Chami K, Msho M. Bladder Cancer. *JAMA* (2020) 324(19):1980. doi: 10.1001/jama.2020.17598
3. Grossman HB, Natale RB, Speights VO, Vogelzang NJ, Trump DJ, et al. Neoadjuvant Chemotherapy Plus Cystectomy Compared With Cystectomy Alone for Locally Advanced Bladder Cancer. *N Engl J Med* (2003) 349(9):859–66. doi: 10.1056/nejmoa022148
4. Von Der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. *J Clin Oncol* (2000) 18(17):3068–77. doi: 10.1002/jco.2000.18.17.3068
5. De Santis M, Bellmunt J, Mead G, Kerst M, Leahy M, Maroto P, et al. Randomized Phase II/III Trial Assessing Gemcitabine/Cisplatin and Methotrexate/Cisplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986. *J Clin Oncol* (2012) 30(2):191–9. doi: 10.1200/jco.2011.37.3571
6. Sternberg CN, De Mulder P, Schornagel JH, Theodores C, Fossa SD, van Oosterom AT, et al. Seven Year Update of an EORTC Phase III Trial of High-Dose Intensity M-VAC Chemotherapy and G-CSF Versus Classical M-VAC in Advanced Urothelial Tract Tumours. *Eur J Cancer* (2006) 42(1):50–4. doi: 10.1016/j.eucarcinog.2005.08.032
7. Starva T, Hoffmann MJ, Olah C, Stekely E, Kiss A, Hess J, et al. MMP-7 Serum and Tissue Levels Are Associated With Poor Survival in Platinum-Treated Bladder Cancer Patients. *Diagnostics* (2020) 11(1):48. doi: 10.3390/diagnostics11010048
8. Olah C, Tschiridewahn S, Hoffmann MJ, Kraft H, Hadachisk B, Nyirady P, et al. Soluble Syndecan-1 Levels Are Associated With Survival in Platinum-Treated Bladder Cancer Patients. *Diagnostics* (2020) 10(11):864. doi: 10.3390/diagnostics10110864
9. Jiang Q, Fu Q, Chang Y, Liu Z, Zhang J, Xu L, et al. CD19+ Tumor-Infiltrating B-Cells Prime CD4+ T-Cell Immunity and Predict Platinum-Based Chemotherapy Efficacy in Muscle-Invasive Bladder Cancer. *Cancer Immunol Immunother* (2019) 68(1):45–56. doi: 10.1007/s00262-019-2250-9
10. Dudek AM, Van Kampen JGM, Witjes JA, Kiemeney LALM, Verhaegh GW. LINC00857 Expression Predicts and Mediates the Response to Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer. *Cancer Med* (2018) 7(7):3342–50. doi: 10.1002/cam4.1570
11. Lv J, Zhu Y, Ji A, Zhang Q, Liao G. Mining TCGA Database for Tumor Mutation Burden and Their Clinical Significance in Bladder Cancer. *Biosci Rep* (2020) 40(4):1–12. doi: 10.1042/bsr20194337
12. Cancer.gov. *The Cancer Genome Atlas Program*. Available at: https://www.cancer.gov/about-nct/organization/ccg/research/structural-genomics/tca.
13. Kamoun A. A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer: Eur Urol (2020) 77(4):420–33. doi: 10.1016/j.eururo.2019.09.006 Elsevier Enhanced Reader.
14. Alifrangis C, McGovern U, Freeman A, Powles T, Linch M. Molecular and Histopathology Directed Therapy for Advanced Bladder Cancer. *Nat Rev Urol* (2019) 16(8):2019. doi: 10.1038/s41571-019-0208-0
15. Soria F, Krabbe L-M, Todenhöfer T, Dobruch J, Mitra AP, Inman BA, et al. Molecular Markers in Bladder Cancer. *World J Urol* (2019) 37(1):31–40. doi: 10.1007/s00345-018-2503-4
16. Touat M, Illane E, Postel-Vinay S, André F, Soria J-C. Targeting FGFR Signaling in Cancer. *Cancer Res* (2015) 21(12):2684–94. doi: 10.1158/1078-0432.ccr-14-2329
17. Wilczewicz M, Hryniewicz R, Grywalska E, Sochojad T, Leksowski T, Rolinski J, et al. Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives. *Cancers* (2020) 12(5):1181. doi: 10.3390/cancers12051181
18. Roche. *Roche Provides Update on Tencertia US Indication in Prior-Platinum Treated Metastatic Bladder Cancer*. Available at: https://www.roche.com/media/releases/med-cor-2021-03-08.htm (Accessed on 13 March 2021).
19. AstraZeneca. *Voluntary Withdrawal of Imfinzi Indication in Advanced Bladder Cancer in the US*. Available at: https://www.astrazeneca.com/content/astrazeneca/media-centre/press-releases/2021/voluntary-withdrawal-imfinzi-us-bladder-indication.html (Accessed May 3, 2021).
25. Powles T, O
32. Balar AV, Kulkarni GS, Uchio EM, Boormans J, Mourey L, Krieger LEM, et al. EF
27. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Atezolizumab With or Without Chemotherapy in Metastatic Urothelial Cancer (IMvigor130): A Multicentre, Randomised, Placebo-Controlled Phase 3 Trial. *Lancet* (2020) 395(10236):1547–57. doi: 10.1016/s0140-6736(20)30230-0

25. Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, et al. Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. *J Clin Oncol* (2017) 35(19):2117–24. doi: 10.1200/jco.2016.71.6795

25. Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumrayi R, et al. Avelumab in Metastatic Urothelial Carcinoma After Platinum Failure (JAVELIN Solid Tumor): Pooled Results From Two Expansion Cohorts of an Open-Label, Phase 1 Trial. *Lancet Oncol* (2018) 19(1):51–64. doi: 10.1016/S1470-2045(17)30900-2

25. Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, et al. First-Line Pembrolizumab in Castration-Ineligible Patients With Locally Advanced and Unresectable or Metastatic Urothelial Cancer (KEYNOTE-052): A Multicentre, Single-Arm, Phase 2 Study. *Lancet Oncol* (2017) 18(11):1483–92. doi: 10.1016/S1470-2045(17)30616-2

25. Balar AV, Kulkarni GS, Uchio EM, Boormans J, Mourey L, Krieger LEM, et al. Keynote 057: Phase II Trial of Pembrolizumab (Pembro) for Patients (Pts) With High-Risk (HR) Nonmucosal Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG). *J Clin Oncol* (2019) 37(7):350–0. doi: 10.1200/jco.2019.37.7_suppl.350

25. Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQM, Juco J, et al. Safety and Activity of Pembrolizumab in Patients With Locally Advanced or Metastatic Urothelial Cancer (KEYNOTE-012): A Non-Randomised, Open-Label, Phase 1b Study. *Lancet Oncol* (2017) 18(2):212–20. doi: 10.1016/S1470-2045(17)30007-4

25. Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, et al. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. *J Clin Oncol* (2018) 36(16):1579–87. doi: 10.1200/JCO.2017.76.9562

25. Suzman DL, Agrawal S, Ning YM, Maher VE, Fernandes LL, Karuri S, et al. FDA Approval Summary: Pembrolizumab or Pembrolizumab for the Treatment of Patients With Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. *Oncologist* (2019) 24(4):563–9. doi: 10.1634/theoncologist.2018-0084

20. Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. *Mol Cancer Ther* (2015) 14(4):847–56. doi: 10.1158/1535-7594.MCT-14-0983

20. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in Patients With Locally Advanced and Metastatic Urothelial Carcinoma Who Have Progressed Following Treatment With Platinum-Based Chemotherapy: A Single-Arm, Multicentre, Phase 2 Trial. *Lancet* (2016) 387(10031):1909–20. doi: 10.1016/s0140-6736(16)00561-4

20. Necchi A, Joseph RW, Loriot Y, Hoffman-Censits J, Perez-Garcia JL, Petrylak DP, et al. Atezolizumab in Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma: Post-Progression Outcomes From the Phase II IMVigor210 Study. *Ann Oncol* (2017) 28(12):3044–50. doi: 10.1093/annonc/mdx318

20. Galakly MD, Arija JA, Banias A, Davis ID, De Santis M, Kikuchi E, et al. Atezolizumab With or Without Chemotherapy in Metastatic Urothelial Cancer (IMvigor130): A Multicentre, Randomised, Placebo-Controlled Phase 3 Trial. *Lancet* (2020) 395(10236):1547–57. doi: 10.1016/s0140-6736(20)30230-0

20. Massard C, Gordon MS, Sharma S, Rafi S, Wainberg ZA, Luke J, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. *J Clin Oncol* (2016) 34(26):3119–25. doi: 10.1200/jco.2016.67.9761

20. Powles T, O’Donnell PH, Massard C, Arkenau H, Friedlander TW, Holmes CJ, et al. Safety and Efficacy of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma. *JAMA Oncol* (2017) 3(9):e172411. doi: 10.1001/jamaoncol.2017.2411

20. Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulos P, Calvo E, et al. Nivolumab Monotherapy in Recurrent Metastatic Urothelial Carcinoma (CheckMate 032): A Multicentre, Open-Label, Two-Stage, Multi-Arm, Phase 1/2 Trial. *Lancet Oncol* (2016) 17(11):1190–8. doi: 10.1016/s1470-2045(16)30496-x

20. Sharma P, Retz M, Siefer-Radtk A, Baron A, Necchi A, Bedke J, et al. Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy (CheckMate 275): A Multicentre, Single-Arm, Phase 2 Trial. *Lancet Oncol* (2017) 18(3):312–22. doi: 10.1016/s1470-2045(17)30065-7

20. Sharma P, Siefer-Radtk A, De Braud F, Basso U, Calvo E, Bono P, et al. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. *J Clin Oncol* (2019) 37(19):1608–16. doi: 10.1200/jco.2019.00538
62. Van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, FDA Panel Endorses Atezolizumab for Frontline Metastatic Urothelial Carcinoma. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/atezolizumab-keytruda-advanced-or-metastatic-urothelial-carcinoma (Accessed May 3, 2021).

63. Vuky J, Balar AV, Castellano D, O’Donnell P, Grivas P, Bellmunt J, et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol (2020) 38(23):2658–66. doi: 10.1200/JCO.19.01213

64. Bellmunt J, De Wit R, Vaughn DJ, Fradet Y, Lee J, Fong L, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med (2017) 376(11):1015–26. doi: 10.1056/nejmoa1613683

65. FDA. FDA Approves New, Targeted Treatment for Bladder Cancer. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-new-targeted-treatment-bladder-cancer (Accessed 14 March 2021).

66. FDA. FDA Grants Accelerated Approval to Enfortumab Vedotin-Efjvy for Metastatic Urothelial Cancer. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-enfortumab-vedotin-efjvy-metastatic-urothelial-cancer (Accessed 14 March 2021).

67. Heath EL, Rosenberg JE. The Biology and Rationale of Targeting Nectin-4 in Urothelial Cancer. Nat Rev Urol (2021) 18(2):93–103. doi: 10.1038/s41585-020-00394-5

68. Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee J, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med (2021) 384(12):1125–35. doi: 10.1056/nejmoa2035807

69. FDA. FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sacituzumab-govitecan-advanced-urothelial-cancer.

70. Petrylak DP, De Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, et al. Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Metastatic Urothelial Cancer After Platinum-Based Therapy (RANGE): A Randomised, Double-Blind, Phase 3 Trial. Lancet (2017) 390(10109):2266–77. doi: 10.1016/s0140-6736(17)32365-6

71. FDA. FDA Approves Pembrolizumab for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer (Accessed 14 March 2021).

72. Lammers RJM, Witjes WPJ, Janzing-Pastors MHD, Caris CTM, Witjes JA. Intracutaneous and Intravesical Immunotherapy With Keyhole Limpet Hemocyanin Compared With Intravesical Mitomycin in Patients With Non–Muscle-Invasive Bladder Cancer: Results From a Prospective Randomized Phase III Trial. J Clin Oncol (2012) 30(18):2273–9. doi: 10.1200/jco.2011.39.2936

73. Prasad NNG, Muddukrishna SN. Quality of Transurethral Resection of Bladder Tumor Procedure Influenced a Phase III Trial Comparing the Effect of KLH and Mitomycin C. Trials (2017) 18(1). doi: 10.1186/s13063-017-1843-5

74. Boorjian SA, Alemozaffar M, Koney BR, Shore ND, Gomez LA, Karmam AM, et al. Intravesical Nadofarfagene Firadavenoc Gene Therapy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Open-Label, Repeat-Dose Clinical Trial. Lancet Oncol (2021) 22(1):107–17. doi: 10.1016/s1470-2045(20)30540-4

75. Tang B, Yan X, Sheng X, Si L, Cui C, Kong Y, et al. Safety and Clinical Activity With an Anti-PD-1 Antibody S801 in Advanced Melanoma or Urologic Cancer Patients. J Hematol Oncol (2019) 12(1). doi: 10.1186/s13045-018-0693-2

76. Schmid SC, Koll FJ, Rödel C, Maisch P, Sauter A, Beckert F, et al. Radiation Therapy Before Radical Cystectomy Combined With Immunotherapy in Locally Advanced Bladder Cancer—Study Protocol of a Prospective, Single-Arm, Multicenter Phase II Trial (RACE it). BMC Cancer (2020) 20(1):8. doi: 10.1186/s12885-019-6503-6

77. Schüler M, Cho BC, Sayehimi CM, Navarro A, Soo RA, Richy H, et al. Rogaritinib in Patients With Advanced Cancers Selected by FGFR mRNA Expression: A Phase 1 Dose-Escalation and Dose-Expansion Study. Lancet Oncol (2019) 20(10):1454–6. doi: 10.1016/s1470-2045(19)30412-7

78. Papadopoulou KP, El-Rayes BF, Tolcher AW, Patnaik A, Rosco DW, Harvey RD, et al. A Phase 1 Study of ARQ 087, an Oral Pan-FGFR Inhibitor in Patients With Advanced Solid Tumours. Br J Cancer (2017) 117(11):1592–9. doi: 10.1038/bjc.2017.330

79. Apolo AB, Karzai FH, Trepel JB, Alarcon S, Lee S, Lee M, et al. A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. J Hematol Oncol (2016) 15(1):77–85. doi: 10.1186/s13045-016-0505-0

80. Herbst RS, Arkenau H-T, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, et al. Ramucirumab Plus Pembrolizumab in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer, Gastro-oesophageal Cancer, or Urothelial Carcinomas (IVDF): A Multicohort, Non-Randomised, Open-Label, Phase 1a/b Trial. Lancet Oncol (2019) 20(8):1109–23. doi: 10.1016/s1470-2045(19)30458-9
81. De Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels J-P, Arkenau H-T, et al. Tisotumab Vedotin in Patients With Advanced or Metastatic Solid Tumours (Innovent 201: A First-in-Human, Multicentre, Phase 1–2 Trial. Lancet Oncol (2020) 21(3):383-93. doi: 10.1016/S1470-2045(20)30859-3.

82. Cibowdny HJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade IL, 3rd, et al. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol (2016) 34 (18):2165–71. doi: 10.1200/jco.2015.66.3047.

83. Serent E,Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeye V, et al. Phase II Study of Everolimus in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract: Clinical Activity, Molecular Response, and Biomarkers. Ann Oncol (2012) 23 (10):2663–70. doi: 10.1093/annonc/mds057.

84. Mihlowsky MI, Iyer G, Regazzi AM, Al-Ahmadi H, Gerst SR, Ostrovnya L, et al. Phase II Study of Everolimus in Metastatic Urothelial Cancer. BJU Int (2013) 112(4):462–70. doi: 10.1111/bju.121720.

85. Pulido M, Roubaud G, Cazeau A-L, Mahammedi H, Vedrine L, Joly F, et al. Safety and Efficacy of Temsirolimus as Second Line Treatment for Patients With Recurrent Bladder Cancer. BMC Cancer (2018) 18(1):194. doi: 10.1186/s12885-018-4059-5.

86. Apolo AB, Nadal R, Tomita Y, Davarananh NN, Cordes LM, Steinberg SM, et al. Clinical Significance of a Second-Line Chemotherapy Regimen With Pazopanib (E/P) Benefit Genomically Selected Patients With Metastatic Urothelial Carcinoma. Br J Cancer (2018) 119(6):707–16. doi: 10.1038/s41416-018-0262-9.

87. Sieker-Radke A, Zhang X-Q, Guo CC, Shen Y, Pirolo KE, Sabir S, et al. A Phase I Study of a Tumor-Targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers. Mol Ther (2016) 24(8):1484–91. doi: 10.1038/mt.2016.118.

88. Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, et al. Apatorsen Plus Docetaxel Versus Docetaxel Alone in Platinum-Resistant Metastatic Urothelial Carcinoma (Vinson): Phase II Trial. Oncologist (2019) 24(6):745. doi: 10.1634/theoncologist.2018-0795.

89. Bellmunt J, Lalani A-KA, Jacobus S, Wankowicz SA, Polack E, Takeda DY, et al. Everolimus and Pazopanib (E/P) Benefit Genomically Selected Patients With Metastatic Urothelial Carcinoma. Br J Cancer (2019) 119(6):707–16. doi: 10.1038/s41416-018-0262-9.

90. Siolkens R, Zhang X-Q, Guo CC, Shen Y, Pirolo KE, Sabir S, et al. A Phase I Study of a Tumor-Targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers. Mol Ther (2016) 24(8):1484–91. doi: 10.1038/mt.2016.118.

91. Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, et al. Apatorsen Plus Docetaxel Versus Docetaxel Alone in Platinum-Resistant Metastatic Urothelial Carcinoma (Vinson): Phase II Trial. Oncologist (2019) 24(6):745. doi: 10.1634/theoncologist.2018-0795.

92. Apolo AB, Nadal R, Tomita Y, Davarananh NN, Cordes LM, Steinberg SM, et al. Clinical Significance of a Second-Line Chemotherapy Regimen With Pazopanib (E/P) Benefit Genomically Selected Patients With Metastatic Urothelial Carcinoma. Br J Cancer (2018) 119(6):707–16. doi: 10.1038/s41416-018-0262-9.

93. Sieker-Radke A, Zhang X-Q, Guo CC, Shen Y, Pirolo KE, Sabir S, et al. A Phase I Study of a Tumor-Targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers. Mol Ther (2016) 24(8):1484–91. doi: 10.1038/mt.2016.118.

94. Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, et al. Apatorsen Plus Docetaxel Versus Docetaxel Alone in Platinum-Resistant Metastatic Urothelial Carcinoma (Vinson): Phase II Trial. Oncologist (2019) 24(6):745. doi: 10.1634/theoncologist.2018-0795.

95. Bellmunt J, Lalani A-KA, Jacobus S, Wankowicz SA, Polack E, Takeda DY, et al. Everolimus and Pazopanib (E/P) Benefit Genomically Selected Patients With Metastatic Urothelial Carcinoma. Br J Cancer (2019) 119(6):707–16. doi: 10.1038/s41416-018-0262-9.

96. Choi YJ, Lee SH, Lee JL, Ahn JH, Lee KH, You D, et al. Phase II Study of Pazopanib in Combination With Pazopanib in Patients With Advanced Urothelial Carcinoma: The PECULIAR Study (KCSG–10–17). Br J Cancer (2015) 112(2):246–51. doi: 10.1038/bjc.2015.37.

97. Cao Y, He Y, Chen H, He S, Gu Y, Wang X, et al. Phase I Study of Gemcitabine-Cisplatin Versus Permetrexed Cisplatin for Patients With Advanced or Metastatic Bladder Cancer. J BUON (2018) 23(2):475–81.
Cancer. Cancer Immunol Immunother (2018) 67(9):1371–80. doi: 10.1007/s00262-018-2197-x

113. Derré L, Cesson V, Lucca I, Cerantola V, Valerio M, Fritschi U, et al. Intravesical Bacillus Calmette Guerin Combined With a Cancer Vaccine Increases Local T-Cell Responses in Non-Muscle-Invasive Bladder Cancer Patients. Clin Cancer Res (2017) 23(3):717–25. doi: 10.1158/1078-0432.ccr-16-1189

114. Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, et al. Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol (2017) 35(30):3410–6. doi: 10.1200/jco.2017.72.3064

115. Arends TJH, Lammers RJM, Falke J, Van der Heijden AG, Rustighini I, Pozzi R, et al. Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer (2015) 13(3):204–9.e2. doi: 10.1016/j.clgc.2014.12.010

116. Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, et al. A Phase 2 Study of TMX-101, Intravesical Imiquimod, for the Treatment of Carcinoma In Situ Bladder Cancer. Urol Oncol (2017) 35(2):39.e1–7. doi: 10.1016/j.urolonc.2016.09.006

117. Balboni B, El Hassouni B, Honeywell RJ, Sarkisjan D, Giovannetti E, Poore J, et al. RX-3117 (Fluorocyclopentenyl Cytosine): A Novel Specific Antimetabolite for Selective Cancer Treatment. Expert Opin Invest Drugs (2019) 28(4):311–22. doi: 10.1080/13543784.2019.1583742

118. Springuel L, Lonez C, Alexandre B, Van Cutsem E, Machiels JH, Van Den Eynde M, et al. Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies. BioDrugs (2019) 33(5):515–37. doi: 10.1007/s40259-019-00368-z

119. Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd, et al. An Open Label, Single-Arm, Phase II Multicenter Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients With BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: Interim Results. Urol Oncol (2018) 36(10):440–7. doi: 10.1016/j.urolonc.2017.07.005

120. Soliman G. The Role of Mechanistic Target of Rapamycin (mTOR) Complexes Signaling in the Immune Responses. Nutrients (2013) 5(6):2231–57. doi: 10.3390/nu5062231

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Nelson, Hong and Jana. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.